Last 12 months
Inside the activity.
0 purchase rows · 153 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 25 |
| Dec 2025 | 0 | 13 |
| Jan 2026 | 0 | 14 |
| Feb 2026 | 0 | 24 |
| Mar 2026 | 0 | 12 |
| Apr 2026 | 0 | 9 |
| May 2026 | 0 | 23 |
| Jun 2026 | 0 | 20 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 7 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2020 Filed Mar 4, 2020 22:55 UTC |
Kumar NeilDirector · CEO and President
|
SaleCommon Stock | 995 | $33.33 | $33,159.47 |
DisclosureSEC source: 0000899243-20-006988 · doc4.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,665,419 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F5 · price: Represents the weighted average sale price of the shares sold from $33.30 to $33.37 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 22:55 UTC |
Kumar NeilDirector · CEO and President
|
SaleCommon Stock | 59,305 | $32.53 | $1,929,411.08 |
DisclosureSEC source: 0000899243-20-006988 · doc4.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,666,414 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F4 · price: Represents the weighted average sale price of the shares sold from $32.26 to $33.25 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 22:55 UTC |
Kumar NeilDirector · CEO and President
|
SaleCommon Stock | 39,653 | $31.88 | $1,264,312.11 |
DisclosureSEC source: 0000899243-20-006988 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,725,719 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $31.26 to $32.25 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4, 5, 6, 7 and 8. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| February 12, 2020 Filed Feb 15, 2020 01:02 UTC |
DANIELS RONALD JDirector
|
GrantStock Option (Right to Buy) · Derivative | 91,554 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0000899243-20-004766 · doc4.xml · derivative · entry 1 DANIELS RONALD J · CIK 0001164475 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,554 Underlying: Common Stock · 91,554 shares Expires 2030-02-11 F1 · derivative.exercise_date: The shares subject to this option vest and become exercisable in three annual installments after February 12, 2020, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| February 12, 2020 Filed Feb 15, 2020 00:16 UTC |
MOMTAZEE JAMES CDirector
|
GrantStock Option (Right to Buy) · Derivative | 24,927 | $0.00 Strike: $34.65 | $0.00 |
DisclosureSEC source: 0000899243-20-004747 · doc4.xml · derivative · entry 2 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,927 Underlying: Common Stock · 24,927 shares Expires 2030-02-11 Read SEC document |
| February 12, 2020 Filed Feb 15, 2020 00:16 UTC |
MOMTAZEE JAMES CDirector
|
GrantCommon Stock | 8,491 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-004747 · doc4.xml · nonDerivative · entry 1 MOMTAZEE JAMES C · CIK 0001209181 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,491 Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:48 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-004549 · doc4.xml · derivative · entry 3 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,000 Underlying: Common Stock · 2,000 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F3 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:48 UTC |
Turtle CameronSee Remarks
|
SaleCommon Stock | 2,000 | $37.28 | $74,564.20 |
DisclosureSEC source: 0000899243-20-004549 · doc4.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,823 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $37.00 to $37.57 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 11, 2020 Filed Feb 14, 2020 01:48 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionCommon Stock | 2,000 | $17.00 | $34,000.00 |
DisclosureSEC source: 0000899243-20-004549 · doc4.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,823 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. Read SEC document |
| February 10, 2020 Filed Feb 13, 2020 00:03 UTC |
HOMCY CHARLES JDirector · Chairman of Pharmaceuticals
|
SaleCommon Stock | 20,000 | $36.00 | $720,000.00 |
DisclosureSEC source: 0000899243-20-004375 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,342,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2019. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 22:40 UTC |
Kumar NeilDirector · CEO and President
|
SaleCommon Stock | 30,893 | $34.87 | $1,077,390.29 |
DisclosureSEC source: 0000899243-20-003696 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · CEO and President 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,765,372 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $34.48 to $35.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| February 04, 2020 Filed Feb 5, 2020 21:57 UTC |
STEPHENSON BRIAN CSee Remarks
|
SaleCommon Stock | 4,973 | $34.52 | $171,692.33 |
DisclosureSEC source: 0000899243-20-003289 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 348,316 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F3 · price: Represents the weighted average sale price of the shares sold from $34.18 to $35.08 per share. Read SEC document |
| February 04, 2020 Filed Feb 5, 2020 22:04 UTC |
Kumar NeilDirector · See Remarks
|
SaleCommon Stock | 54,951 | $34.55 | $1,898,386.70 |
DisclosureSEC source: 0000899243-20-003303 · doc4.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,796,265 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F5 · price: Represents the weighted average sale price of the shares sold from $34.20 to $35.11 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 21:57 UTC |
STEPHENSON BRIAN CSee Remarks
|
SaleCommon Stock | 5,827 | $34.90 | $203,378.62 |
DisclosureSEC source: 0000899243-20-003289 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 353,289 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $34.47 to $35.21 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 2 and 3. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:04 UTC |
Kumar NeilDirector · See Remarks
|
SaleCommon Stock | 2,100 | $35.20 | $73,914.12 |
DisclosureSEC source: 0000899243-20-003303 · doc4.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,851,216 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F4 · price: Represents the weighted average sale price of the shares sold from $35.16 to $35.27 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:04 UTC |
Kumar NeilDirector · See Remarks
|
SaleCommon Stock | 32,056 | $34.92 | $1,119,308.97 |
DisclosureSEC source: 0000899243-20-003303 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,853,316 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $34.16 to $35.15 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4 and 5. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 22:00 UTC |
HENDERSON MICHAEL THOMASSee Remarks
|
SaleCommon Stock | 3,975 | $34.90 | $138,729.49 |
DisclosureSEC source: 0000899243-20-003297 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,287 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $34.63 to $35.20 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 14, 2020 Filed Jan 17, 2020 00:17 UTC |
HOMCY CHARLES JDirector · Chairman of Pharmaceuticals
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-001340 · doc4.xml · derivative · entry 3 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,463 Underlying: Common Stock · 10,000 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2019. F3 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| January 14, 2020 Filed Jan 17, 2020 00:17 UTC |
HOMCY CHARLES JDirector · Chairman of Pharmaceuticals
|
SaleCommon Stock | 10,000 | $35.00 | $350,000.00 |
DisclosureSEC source: 0000899243-20-001340 · doc4.xml · nonDerivative · entry 2 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,362,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2019. Read SEC document |
| January 14, 2020 Filed Jan 17, 2020 00:17 UTC |
HOMCY CHARLES JDirector · Chairman of Pharmaceuticals
|
Exercise / conversionCommon Stock | 10,000 | $17.00 | $170,000.00 |
DisclosureSEC source: 0000899243-20-001340 · doc4.xml · nonDerivative · entry 1 HOMCY CHARLES J · CIK 0001192591 · Director · Chairman of Pharmaceuticals 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,372,291 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2019. F2 · balance_after: Includes 865 shares acquired by the Reporting Person on December 31, 2019 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 22:15 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $17.00 | $0.00 |
DisclosureSEC source: 0000899243-20-000991 · doc4.xml · derivative · entry 4 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F4 · derivative.exercise_date: The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 22:15 UTC |
Turtle CameronSee Remarks
|
SaleCommon Stock | 4,802 | $34.71 | $166,669.74 |
DisclosureSEC source: 0000899243-20-000991 · doc4.xml · nonDerivative · entry 3 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,823 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F3 · price: Represents the weighted average sale price of the shares sold from $34.515 to $35.075 per share. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 22:15 UTC |
Turtle CameronSee Remarks
|
SaleCommon Stock | 8,005 | $34.17 | $273,541.26 |
DisclosureSEC source: 0000899243-20-000991 · doc4.xml · nonDerivative · entry 2 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,625 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $33.51 to $34.505 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 22:15 UTC |
Turtle CameronSee Remarks
|
Exercise / conversionCommon Stock | 10,000 | $17.00 | $170,000.00 |
DisclosureSEC source: 0000899243-20-000991 · doc4.xml · nonDerivative · entry 1 Turtle Cameron · CIK 0001758363 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,630 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 01:55 UTC |
STEPHENSON BRIAN CSee Remarks
|
SaleCommon Stock | 3,536 | $32.31 | $114,246.04 |
DisclosureSEC source: 0000899243-20-000654 · doc4.xml · nonDerivative · entry 6 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 359,116 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on [December 3, 2019]. F6 · price: Represents the weighted average sale price of the shares sold from $32.00 to $32.99 per share. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 01:55 UTC |
STEPHENSON BRIAN CSee Remarks
|
SaleCommon Stock | 100 | $31.94 | $3,194.00 |
DisclosureSEC source: 0000899243-20-000654 · doc4.xml · nonDerivative · entry 5 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,652 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on [December 3, 2019]. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 02:30 UTC |
HENDERSON MICHAEL THOMASSee Remarks
|
SaleCommon Stock | 26 | $33.00 | $858.01 |
DisclosureSEC source: 0000899243-20-000660 · doc4.xml · nonDerivative · entry 5 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,262 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F7 · price: Represents the weighted average sale price of the shares sold from $32.91 to $33.14 per share. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 02:30 UTC |
HENDERSON MICHAEL THOMASSee Remarks
|
SaleCommon Stock | 332 | $32.28 | $10,716.59 |
DisclosureSEC source: 0000899243-20-000660 · doc4.xml · nonDerivative · entry 4 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,288 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F6 · price: Represents the weighted average sale price of the shares sold from $31.87 to $32.86 per share. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 02:15 UTC |
Kumar NeilDirector · See Remarks
|
SaleCommon Stock | 6,668 | $32.88 | $219,249.84 |
DisclosureSEC source: 0000899243-20-000659 · doc4.xml · nonDerivative · entry 6 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,885,372 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F7 · price: Represents the weighted average sale price of the shares sold from $32.695 to $33.10 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| January 03, 2020 Filed Jan 7, 2020 02:15 UTC |
Kumar NeilDirector · See Remarks
|
SaleCommon Stock | 77,271 | $32.14 | $2,483,706.30 |
DisclosureSEC source: 0000899243-20-000659 · doc4.xml · nonDerivative · entry 5 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,892,040 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F6 · price: Represents the weighted average sale price of the shares sold from $31.69 to $32.68 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 01:55 UTC |
STEPHENSON BRIAN CSee Remarks
|
SaleCommon Stock | 30 | $35.17 | $1,055.10 |
DisclosureSEC source: 0000899243-20-000654 · doc4.xml · nonDerivative · entry 4 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,752 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on [December 3, 2019]. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 01:55 UTC |
STEPHENSON BRIAN CSee Remarks
|
SaleCommon Stock | 622 | $34.23 | $21,292.68 |
DisclosureSEC source: 0000899243-20-000654 · doc4.xml · nonDerivative · entry 3 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,782 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on [December 3, 2019]. F5 · price: Represents the weighted average sale price of the shares sold from $34.08 to $34.40 per share. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 01:55 UTC |
STEPHENSON BRIAN CSee Remarks
|
SaleCommon Stock | 4,217 | $33.47 | $141,156.06 |
DisclosureSEC source: 0000899243-20-000654 · doc4.xml · nonDerivative · entry 2 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 363,404 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on [December 3, 2019]. F4 · price: Represents the weighted average sale price of the shares sold from $33.07 to $34.065 per share. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 01:55 UTC |
STEPHENSON BRIAN CSee Remarks
|
SaleCommon Stock | 2,295 | $32.57 | $74,739.43 |
DisclosureSEC source: 0000899243-20-000654 · doc4.xml · nonDerivative · entry 1 STEPHENSON BRIAN C · CIK 0001780030 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 367,621 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on [December 3, 2019]. F2 · price: Represents the weighted average sale price of the shares sold from $32.02 to $33.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4, 5 and 6. F3 · balance_after: Includes 1,470 shares acquired by the Reporting Person on December 31, 2019 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 02:30 UTC |
HENDERSON MICHAEL THOMASSee Remarks
|
SaleCommon Stock | 115 | $34.45 | $3,961.55 |
DisclosureSEC source: 0000899243-20-000660 · doc4.xml · nonDerivative · entry 3 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,620 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F5 · price: Represents the weighted average sale price of the shares sold from $34.34 to $35.17 per share. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 02:30 UTC |
HENDERSON MICHAEL THOMASSee Remarks
|
SaleCommon Stock | 2,002 | $33.61 | $67,290.82 |
DisclosureSEC source: 0000899243-20-000660 · doc4.xml · nonDerivative · entry 2 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,735 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F4 · price: Represents the weighted average sale price of the shares sold from $33.16 to $34.15 per share. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 02:30 UTC |
HENDERSON MICHAEL THOMASSee Remarks
|
SaleCommon Stock | 1,500 | $32.69 | $49,034.10 |
DisclosureSEC source: 0000899243-20-000660 · doc4.xml · nonDerivative · entry 1 HENDERSON MICHAEL THOMAS · CIK 0001779990 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,737 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 29, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $32.15 to $33.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4, 5, 6 and 7. F3 · balance_after: Includes 1,470 shares acquired by the Reporting Person on December 31, 2019 pursuant to the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 02:15 UTC |
Kumar NeilDirector · See Remarks
|
SaleCommon Stock | 100 | $35.17 | $3,517.00 |
DisclosureSEC source: 0000899243-20-000659 · doc4.xml · nonDerivative · entry 4 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,969,311 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 02:15 UTC |
Kumar NeilDirector · See Remarks
|
SaleCommon Stock | 5,077 | $34.19 | $173,560.29 |
DisclosureSEC source: 0000899243-20-000659 · doc4.xml · nonDerivative · entry 3 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,969,411 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F5 · price: Represents the weighted average sale price of the shares sold from $34.02 to $34.70 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 02:15 UTC |
Kumar NeilDirector · See Remarks
|
SaleCommon Stock | 19,793 | $33.41 | $661,341.53 |
DisclosureSEC source: 0000899243-20-000659 · doc4.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,974,488 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F4 · price: Represents the weighted average sale price of the shares sold from $33.02 to $34.01 per share. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| January 02, 2020 Filed Jan 7, 2020 02:15 UTC |
Kumar NeilDirector · See Remarks
|
SaleCommon Stock | 11,091 | $32.55 | $361,042.00 |
DisclosureSEC source: 0000899243-20-000659 · doc4.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,994,281 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 22, 2019. F2 · price: Represents the weighted average sale price of the shares sold from $32.02 to $33.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2, 4, 5, 6 and 7. F3 · ownership.nature: The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 23:08 UTC |
KKR Management Holdings L.P.10% owner
KKR Management Holdings Corp10% owner
|
OtherCommon Stock | 36,900,661 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-20-000250 · form4.xml · nonDerivative · entry 1 KKR Management Holdings L.P. · CIK 0001472693 · 10% owner KKR Management Holdings Corp · CIK 0001472692 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 F1 · kind: Pursuant to an internal reorganization, on January 1, 2020 KKR Management Holdings Corp. was merged into its parent, KKR Group Holdings Corp., and KKR Management Holdings L.P. was merged into KKR Fund Holdings L.P., an existing subsidiary of KKR & Co. Inc. KKR Fund Holdings L.P. was then renamed KKR Group Partnership L.P. As a result, KKR Management Holdings Corp. and KKR Management Holdings L.P. ceased to exist as separate entities. KKR Management Holdings Corp. and KKR Management Holdings L.P. are filing this exit Form 4 to report that they are no longer beneficial owners of securities of BridgeBio Pharma, Inc. (the "Issuer"). KKR Group Partnership L.P. is separately filing a Form 3 to report beneficial ownership of Issuer securities in connection with the above reorganization. This internal reorganization did not involve any purchase or sale of securities of the Issuer. F1 · price: Pursuant to an internal reorganization, on January 1, 2020 KKR Management Holdings Corp. was merged into its parent, KKR Group Holdings Corp., and KKR Management Holdings L.P. was merged into KKR Fund Holdings L.P., an existing subsidiary of KKR & Co. Inc. KKR Fund Holdings L.P. was then renamed KKR Group Partnership L.P. As a result, KKR Management Holdings Corp. and KKR Management Holdings L.P. ceased to exist as separate entities. KKR Management Holdings Corp. and KKR Management Holdings L.P. are filing this exit Form 4 to report that they are no longer beneficial owners of securities of BridgeBio Pharma, Inc. (the "Issuer"). KKR Group Partnership L.P. is separately filing a Form 3 to report beneficial ownership of Issuer securities in connection with the above reorganization. This internal reorganization did not involve any purchase or sale of securities of the Issuer. F2 · ownership.nature: The securities of the Issuer are held by KKR Genetic Disorder L.P. KKR Genetic Disorder GP LLC, as the general partner of KKR Genetic Disorder L.P., KKR Group Partnership L.P., as the sole member of KKR Genetic Disorder GP LLC, KKR Group Holdings Corp., as the general partner of KKR Group Partnership L.P., KKR & Co. Inc., as the sole shareholder of KKR Group Holdings Corp., KKR Management LLP, as the Class B common stockholder of KKR & Co. Inc., and Messrs. Henry R. Kravis and George R. Roberts, as the founding partners of KKR Management LLP, may be deemed to be the beneficial owners having shared voting and investment power with respect to the shares described above. Each of Messrs. Kravis and Roberts disclaims beneficial ownership of the shares held by KKR Genetic Disorder L.P. F3 · ownership.nature: Each of the Reporting Persons may have been deemed to be the beneficial owner of all or a portion of the securities reported herein. The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the Reporting Persons engaged in any transactions subject to Section 16 of the Securities Exchange Act of 1934 or are or were the beneficial owners of any securities reported herein, and the Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document |
| December 30, 2019 Filed Dec 31, 2019 21:05 UTC |
MCCORMICK FRANKChairman of Oncology
|
SaleCommon Stock | 900 | $36.86 | $33,171.66 |
DisclosureSEC source: 0000899243-19-030273 · doc4.xml · nonDerivative · entry 10 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,261,526 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019. F10 · price: Represents the weighted average sale price of the shares sold from $36.5101 to $37.25 per share. Read SEC document |
| December 30, 2019 Filed Dec 31, 2019 21:05 UTC |
MCCORMICK FRANKChairman of Oncology
|
SaleCommon Stock | 16,250 | $35.74 | $580,840.00 |
DisclosureSEC source: 0000899243-19-030273 · doc4.xml · nonDerivative · entry 9 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,262,426 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019. F9 · price: Represents the weighted average sale price of the shares sold from $35.36 to $36.31 per share. Read SEC document |
| December 30, 2019 Filed Feb 14, 2020 01:57 UTC |
Kumar NeilDirector · See Remarks
|
GiftCommon Stock | 66,730 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-004555 · doc5.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,685,365 Read SEC document |
| December 30, 2019 Filed Feb 14, 2020 01:57 UTC |
Kumar NeilDirector · See Remarks
|
GiftCommon Stock | 400,375 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-004555 · doc5.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By Neil Kumar LLC Disclosed balance after: 0 F1 · ownership.nature: The shares were originally held by Neil Kumar LLC, of which the Reporting Person shared voting, investment and dispositive power with the other LLC member. The Reporting Person disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares were beneficially owned by the Reporting Person for Section 16 or any other purposes. Read SEC document |
| December 30, 2019 Filed Feb 14, 2020 22:16 UTC Amendment |
Kumar NeilDirector · See Remarks
|
GiftCommon Stock | 66,730 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-004685 · doc5a.xml · nonDerivative · entry 2 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,685,725 Read SEC document |
| December 30, 2019 Filed Feb 14, 2020 22:16 UTC Amendment |
Kumar NeilDirector · See Remarks
|
GiftCommon Stock | 400,375 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-004685 · doc5a.xml · nonDerivative · entry 1 Kumar Neil · CIK 0001742485 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · By Neil Kumar LLC Disclosed balance after: 0 F1 · ownership.nature: The shares were originally held by Neil Kumar LLC, of which the Reporting Person shared voting, investment and dispositive power with the other LLC member. The Reporting Person disclaims Section 16 beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares were beneficially owned by the Reporting Person for Section 16 or any other purposes. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 21:05 UTC |
MCCORMICK FRANKChairman of Oncology
|
SaleCommon Stock | 100 | $42.93 | $4,293.00 |
DisclosureSEC source: 0000899243-19-030273 · doc4.xml · nonDerivative · entry 8 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,278,576 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 21:05 UTC |
MCCORMICK FRANKChairman of Oncology
|
SaleCommon Stock | 617 | $42.26 | $26,075.78 |
DisclosureSEC source: 0000899243-19-030273 · doc4.xml · nonDerivative · entry 7 MCCORMICK FRANK · CIK 0001257809 · Chairman of Oncology 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,278,676 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on November 27, 2019. F8 · price: Represents the weighted average sale price of the shares sold from $41.87 to $42.84 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.